ddCTP (trilithium)

• UNSPSC Description:

  ddCTP trilithium is one of 2',3'-dideoxyribonucleoside 5'-triphosphates (ddNTPs) that acts as chain-elongating inhibitor of DNA polymerase for DNA sequencing. ddCTP trilithium is a nucleoside analog that targets the reverse trsanscriptase of human immunodeficiency virus (HIV). ddCTP trilithium can be used for AIDS research[1][2].

• Target Antigen:

  DNA/RNA Synthesis; HIV Protease

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Cell Cycle/DNA Damage;Metabolic Enzyme/Protease

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/ddctp-trilithium.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=[P](O[P](O[P](O)(O[Li])=O)(O[Li])=O)(O[Li])OC[C@@H]1CC[C@H](N2C(N=C(N)C=C2)=O)O1

• Molecular Weight:

  468.96

• References & Citations:

  [1]Z G Chidgeavadze, et al. 3'-Fluoro-2',3'-dideoxyribonucleoside 5'-triphosphates: terminators of DNA synthesis. FEBS Lett. 1985 Apr 22;183(2):275-8.|[2]Pelletier H, et al. Structures of ternary complexes of rat DNA polymerase beta, a DNA template-primer, and ddCTP. Science. 1994 Jun 24;264(5167):1891-903.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  93939-77-6